Stock listing

ASX:TLX Telix Pharmaceuticals Limited Share Price

Home listing (ASX) of Telix Pharmaceuticals Limited

Follow Telix Pharmaceuticals Limited into a list and get an email when it puts out news.

Share price · ASX:TLX

$12.92 AUD -0.29 (-2.2%)

Close on Nov 20, 2026

Past year -6.9% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$12.73 – $13.25 AUDNov 20, 2026
Volume
1.48M sharesNov 20, 2026
Market cap
$4.38B AUDAt the close on Nov 20, 2026 · price × 338.8M shares outstanding
52-week range
$8.26 – $18.22 AUDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$32.85M AUDMedian day 1.72M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Telix Pharmaceuticals Limited logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
ASX:TLX · Home$12.92 AUD-0.29 (-2.2%)1,477,613$13.25$13.25$12.73$13.21Close on Nov 20, 2026
NASDAQ:TLX$8.37 USD-0.34 (-3.9%)269,405$8.66$8.70$8.365$8.71Close on Nov 20, 2026
OTC:TLPPF$8.66 USD-0.35 (-3.9%)3,292$8.61$8.66$8.61$9.01Close on Nov 18, 2026
Frankfurt:T3X€7.556 EUR-0.366 (-4.6%)—€7.713€7.717€7.556€7.922Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · ASX:TLX · AUD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$12.92-0.29-2.2%$13.25$13.25$12.731,477,613
$13.21-0.12-0.9%$13.27$13.49$13.141,090,259
$13.33-0.06-0.4%$13.20$13.39$13.041,421,582
$13.39-0.19-1.4%$13.41$13.74$13.371,105,902
$13.58-0.12-0.9%$13.70$13.75$13.48877,947
$13.70-0.32-2.3%$14.12$14.35$13.372,345,160
$14.02+0.22+1.6%$13.45$14.26$13.331,951,626
$13.80-0.13-0.9%$14.10$14.18$13.691,305,809
$13.93+0.26+1.9%$13.68$14.05$13.621,203,866
$13.67-0.41-2.9%$13.80$13.97$13.672,002,751
$14.08+0.76+5.7%$13.80$14.22$13.712,586,196
$13.32+0.32+2.5%$13.03$13.75$13.031,837,418
$13.00-0.08-0.6%$13.00$13.18$12.871,304,985
$13.08-0.05-0.4%$13.02$13.22$12.871,418,249
$13.13-0.35-2.6%$13.56$13.60$12.991,947,400
$13.48+0.42+3.2%$13.35$13.87$13.341,788,720
$13.06+0.27+2.1%$13.10$13.34$12.804,042,702
$12.79-0.06-0.5%$13.00$13.07$12.692,945,488
$12.85-0.34-2.6%$12.90$13.11$12.614,418,896
$13.19-0.47-3.4%$13.56$13.56$12.853,151,131
$13.66-0.86-5.9%$14.28$14.58$13.444,372,393
$14.52-1.24-7.9%$16.00$16.25$14.274,382,368
$15.76+0.36+2.3%$15.45$15.97$15.351,241,406
$15.40-0.33-2.1%$15.38$15.47$14.831,107,461
$15.73+0.65+4.3%$15.20$15.87$14.931,369,067
$15.08-0.26-1.7%$15.49$15.49$14.751,815,274
$15.34-0.44-2.8%$15.51$15.76$15.341,105,381
$15.78-0.52-3.2%$16.10$16.20$15.541,348,264
$16.30+0.45+2.8%$15.95$16.50$15.841,213,896
$15.850.000.0%$15.79$16.04$15.721,026,543
$15.85-0.02-0.1%$15.90$16.02$15.711,297,945
$15.87+0.46+3.0%$15.51$16.27$15.512,364,422
$15.41-0.14-0.9%$15.55$15.73$15.241,114,504
$15.55+0.39+2.6%$15.08$15.67$14.951,268,082
$15.16-0.45-2.9%$15.41$15.51$14.882,579,339
$15.61-0.11-0.7%$15.69$15.86$15.351,632,404
$15.72-0.43-2.7%$16.30$16.30$15.702,533,433
$16.15+0.06+0.4%$16.26$16.46$15.921,976,174
$16.09+0.19+1.2%$15.97$16.34$15.721,770,667
$15.90+0.16+1.0%$15.83$16.29$15.691,553,094
$15.74-0.34-2.1%$16.07$16.18$15.671,811,559
$16.08-0.71-4.2%$16.82$16.82$15.843,343,138
$16.79+1.03+6.5%$16.45$16.94$16.223,659,694
$15.76-2.09-11.7%$17.10$17.40$15.764,371,032
$17.85+0.40+2.3%$17.57$18.11$17.513,062,365
$17.45+0.58+3.4%$16.87$17.83$16.682,277,535
$16.87-0.88-5.0%$17.55$17.74$16.483,613,622
$17.75+1.41+8.6%$16.80$18.22$16.706,277,577
$16.34+0.67+4.3%$17.50$17.65$15.854,723,800
$15.67-1.09-6.5%$16.45$16.61$15.502,193,327
$16.76+0.07+0.4%$16.80$17.00$16.641,759,963
$16.69+0.19+1.2%$16.43$16.77$16.281,109,874
$16.50+0.25+1.5%$16.16$16.59$15.971,119,678
$16.25-0.22-1.3%$16.20$16.50$15.931,122,950
$16.47+0.21+1.3%$16.35$16.66$16.261,527,242
$16.26+0.57+3.6%$15.86$16.51$15.502,058,883
$15.69+0.42+2.8%$15.30$16.00$15.081,568,691
$15.27-0.09-0.6%$15.22$15.30$14.861,638,595
$15.36-0.29-1.9%$15.39$15.59$15.261,092,733
$15.65+0.07+0.4%$15.66$16.15$15.62985,671
$15.58+0.09+0.6%$15.40$15.84$15.171,273,984
$15.49-0.67-4.1%$16.23$16.52$15.441,504,493
$16.160.000.0%$16.18$16.25$15.91995,818
$16.16+0.54+3.5%$15.50$16.39$15.201,683,785
$15.62-1.76-10.1%$16.62$16.76$15.624,587,381
$17.38+0.54+3.2%$17.15$18.13$16.555,205,523
Ticker
ASX:TLX
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
ASX
Currency
AUD

What changed lately

Latest news

Appendix 3Y Maria Rivas

Nov 4, 2026

Closed $14.08 (+5.7%) on Nov 5, 2026

Cancellation of Appendix 2A

Nov 2, 2026

Closed $13.00 (-0.6%) on Nov 3, 2026

Notice of General Meeting

Oct 29, 2026

Closed $13.13 (-2.6%) on Oct 30, 2026

Appendix 3Y Dr Christian Behrenbruch

Oct 26, 2026

Closed $12.79 (-0.5%) on Oct 27, 2026

Appendix 3Y William Jellison

Oct 25, 2026

Closed $12.85 (-2.6%) on Oct 26, 2026

All Telix Pharmaceuticals Limited news

Telix Pharmaceuticals Limited on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
102 in the last 12 months · 404 in all · newest Nov 4, 2026 · oldest 2017
Calls
2 calls with a replay · 2 with a transcript · latest Aug 20, 2026
Decks
63 decks · latest Nov 4, 2026

Where Telix Pharmaceuticals Limited is listed

ListingExchangeCountryCurrency
ASX:TLX · Home listing · This pageASXAustraliaAUD
NASDAQ:TLXNASDAQUnited StatesUSD
LS Exchange:A2H7JKLS ExchangeGermanyEUR
gettex:T3XgettexGermanyEUR
Tradegate:T3XTradegateGermanyEUR
OTC:TLPPFOTCUnited StatesUSD
BOATS:TLXBOATSUnited StatesUSD
Lang & Schwarz:A2H7JKLang & SchwarzGermanyEUR
Frankfurt:T3XFrankfurtGermanyEUR
BMV:TLX1NBMVMexicoMXN
Dusseldorf:T3XDusseldorfGermanyEUR
BIVA:TLX1NBIVAMexicoMXN
Frankfurt:T3X0FrankfurtGermanyEUR
Hamburg:T3XHamburgGermanyEUR
Munich:T3XMunichGermanyEUR
Stuttgart:T3XStuttgartGermanyEUR

Valuation

EV/sales 4.0× against a median of 2.5×: 7th lowest of 11 Pharmaceuticals companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026

Enterprise value
$4.87B AUD
P/E
Loss
EV/sales
4.0×
EV/EBITDA
63.0×
Price/book
5.9×
Gross margin
53.0%
Operating margin
3.7%
Net margin
−0.9%
Debt to equity
1.2×
Beta
No index for this market yet

Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Telix Pharmaceuticals Limited · ASX:TLXUS$2.90BUS$3.22Bn/a4.0×63.0×5.9×−0.9%1.2×n/a
Xeris Biopharma Holdings, Inc. · NASDAQ:XERSUS$3.10BUS$3.16Bn/a8.6×58.9×63.5×−1.8%3.9×0.11
Bausch Health Companies Inc. · TSX:BHCUS$3.08BUS$21.23Bn/a1.9×n/an/a−7.6%n/a0.65
Rubicon Research Limited · NSE:RUBICONUS$3.07BUS$3.05B98.7×14.6×62.8×22.1×14.9%0.1×n/a
Jilin Aodong Pharmaceutical Group Co., Ltd. Class A · SZSE:000623US$2.98BUS$2.56B6.6×7.6×n/a0.6×133.7%0.0×n/a
ACADIA Pharmaceuticals Inc. · NASDAQ:ACADUS$2.96BUS$2.05B8.2×1.7×15.5×2.1×30.1%0.1×0.40
ADMA Biologics Inc · NASDAQ:ADMAUS$2.92BUS$2.99B16.0×5.8×12.0×6.7×35.1%0.5×0.05
Chengdu Kanghong Pharmaceutical Group Co., Ltd. Class A · SZSE:002773US$2.90BUS$1.94B21.1×3.1×n/a2.0×22.1%0.0×n/a
China Medical System Holdings Ltd. · HKEX:867US$2.87BUS$2.13B12.8×1.7×7.7×1.1×18.1%0.1×n/a
Joincare Pharmaceutical Group Industry Co., Ltd. Class A · SSE:600380US$2.80BUS$1.16B16.5×0.6×n/a1.3×8.4%0.1×n/a
Livzon Pharmaceutical Group, Inc. Class A · SZSE:000513US$2.72BUS$1.65B11.7×1.1×n/a1.4×15.2%0.0×n/a
Median of the othersUS$2.94BUS$2.35B14.4×2.5×15.5×2.0×16.7%0.1×0.26

Forecasts

Analysts' consensus from EODHD, read Nov 22, 2026. Not 6ix's view and not investment advice.

Price target
24.17 AUD · Analysts' mean
EPS, year to Dec 2026
0.071 · 11 analysts
Revenue, year to Dec 2026
1.4B · 14 analysts

Team and board

Officers

OfficerRole
Christian BehrenbruchManaging Director & Group Chief Executive Officer
Darren SmithGroup Chief Financial Officer
Darren PattiGroup Chief Operating Officer
Christian KrautkramerGroup General Counsel
Annie KasparianInvestor Relations
Charlene Jaw AssociateDirector Investor Relations
Kyahn WilliamsonSVP, Investor Relations & Corporate Communications
Kenneth ClarkeSVP, Global Regulatory Affairs
Meredith CroweSVP, Global People & Culture
Paul SchafferSVP, Research & Development
Radu CiocanSVP, TMS Radiopharmaceutical Operations
Thorsten MelcherSVP, Global Business Development and Alliance Management
Tom FrommSVP, Corporate Sales
Craig UlrickChief Information Officer
David CadeGroup Chief Medical Officer
Mary JesselGroup Chief of Clinical Affairs

Board

DirectorRole
David GillChair & Independent Non-Executive Director
Jann SkinnerIndependent Non-Executive Director
Maria RivasIndependent Non-Executive Director
Marie McDonaldIndependent Non-Executive Director
Mark NelsonIndependent Non-Executive Director
William JellisonIndependent Non-Executive Director

Events

Next results
Feb 17, 2027 (expected)

Calls

CallWhenStatus
Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings CallThu, Aug 20, 2026 · 7:00 PM ETReplay
Telix Pharmaceuticals (ASX:TLX) Q4 2025 Earnings CallThu, Aug 21, 2025 · 7:30 PM ETReplay

Results days

QuarterResultsShare move
Quarter to Sep 30, 2025Oct 14, 2025+15.3%
Q2 2025Aug 20, 2025 · Before open−3.5%
Quarter to Mar 31, 2025Apr 22, 2025+10.2%
Q4 2024Feb 20, 2025+12.3%
Quarter to Sep 30, 2024Oct 17, 2024+3.4%
Q2 2024Aug 22, 2024 · After close−3.0%
Q1 2024May 22, 2024 · Before open+2.5%
Q4 2023Feb 22, 2024−4.4%
Quarter to Sep 30, 2023Oct 18, 2023−9.4%
Q2 2023Aug 23, 2023 · After close+3.6%
All 18 quarters
QuarterResultsShare move
Q1 2023Apr 17, 2023 · After close+12.7%
Q4 2022Feb 27, 2023 · After close+6.2%
Q3 2022Oct 20, 2022 · Before open−6.7%
Q2 2022Aug 17, 2022 · After close−8.7%
Q1 2022Jun 1, 2022−13.1%
Q4 2021Feb 24, 2022 · Before open−4.5%
Q2 2021Aug 19, 2021+6.0%
Q4 2020Feb 25, 2021−2.0%

Open Events

Decks

DeckKindSlidesDate
Investor Day (November 2026)Investor day94 slidesNov 4, 2026
Investor Day (September 2026)Investor day113 slidesSep 22, 2026
Merger or Acquisition (September 2026)Merger or acquisition36 slidesSep 21, 2026
Telix Pharm — H1 2026 Earnings PresentationEarnings27 slidesAug 21, 2026
William Blair Growth Conference (June 2026)Conference16 slidesJun 2, 2026
Shareholder Meeting (May 2026)Shareholder meeting46 slidesMay 21, 2026
Technical Presentation (April 2026)Technical22 slidesApr 30, 2026
Investor Presentation (April 2026)Investor deck20 slidesApr 14, 2026
Investor Presentation (April 2026)Investor deck20 slidesApr 14, 2026
Earnings Presentation (March 2026)Earnings24 slidesMar 10, 2026
Show 50 decks
DeckKindSlidesDate
FY2025 Earnings PresentationEarnings32 slidesFeb 20, 2026
J.P. Morgan Healthcare Conference 2026Conference25 slidesJan 12, 2026
44th Annual J.P. Morgan Healthcare Conference (January 2026)Conference27 slidesJan 12, 2026
Telix Pharm — H1 2025 Earnings PresentationEarnings38 slidesAug 22, 2025
Investor Day (June 2025)Investor day127 slidesJun 11, 2025
Shareholder Meeting (May 2025)Shareholder meeting15 slidesMay 21, 2025
FY2024 Earnings PresentationEarnings41 slidesFeb 21, 2025
Merger or Acquisition (January 2025)Merger or acquisition14 slidesJan 13, 2025
Merger or Acquisition (January 2025)Merger or acquisition14 slidesJan 13, 2025
JP Morgan 43rd Annual Healthcare Conference 2025Conference33 slidesJan 13, 2025
Merger or Acquisition (November 2024)Merger or acquisition14 slidesNov 19, 2024
H1 2024 Earnings PresentationEarnings24 slidesAug 22, 2024
Investor Presentation (July 2024)Investor deck24 slidesJul 23, 2024
Shareholder Meeting (May 2024)Shareholder meeting18 slidesMay 22, 2024
Shareholder Meeting (April 2024)Shareholder meeting16 slidesApr 5, 2024
Merger or Acquisition (March 2024)Merger or acquisition12 slidesMar 5, 2024
FY2023 Earnings PresentationEarnings25 slidesFeb 22, 2024
Merger or Acquisition (February 2024)Merger or acquisition12 slidesFeb 8, 2024
J.P. Morgan Healthcare Conference 2024Conference31 slidesJan 8, 2024
Q3 2023 Earnings PresentationEarnings22 slidesOct 18, 2023
H1 2023 Earnings PresentationEarnings31 slidesAug 23, 2023
Q2 2023 Earnings PresentationEarnings26 slidesJul 19, 2023
Fact Sheet (June 2023)Fact sheet5 slidesJune 2023
Shareholder Meeting (May 2023)Shareholder meeting14 slidesMay 24, 2023
Corporate Update (April 2023)Corporate update14 slidesApr 27, 2023
Q1 2023 Earnings PresentationEarnings21 slidesApr 17, 2023
FY2022 Earnings PresentationEarnings32 slidesFeb 27, 2023
Technical Presentation (February 2023)Technical19 slidesFeb 21, 2023
Q4 2022 Earnings PresentationEarnings18 slidesJan 18, 2023
J.P. Morgan Healthcare Conference 2023Conference33 slidesJan 12, 2023
Technical Presentation (November 2022)Technical17 slidesNov 7, 2022
Q3 2022 Earnings PresentationEarnings17 slidesOct 20, 2022
H1 2022 Earnings PresentationEarnings33 slidesAug 18, 2022
Jefferies Global Healthcare Conference 2022Conference32 slidesJun 10, 2022
FY2021 Earnings PresentationEarnings33 slidesFeb 24, 2022
Investor Presentation (January 2022)Investor deck62 slidesJan 24, 2022
JP Morgan Virtual Healthcare Conference, January 2022Conference45 slidesJan 11, 2022
Investor Presentation (November 2021)Investor deck38 slidesNov 16, 2021
H1 2021 Earnings PresentationEarnings31 slidesAug 19, 2021
Jefferies Healthcare Conference 2021Conference25 slidesJun 2, 2021

This page holds 50 of 63 decks. Open Decks

Open Decks

Financings

RaiseDate
At-the-market programme of new fully paid ordinary shares in the form of American Depository Shares (ADSs)
Announced: Morgan Stanley & Co. LLC +1
Dealers: Morgan Stanley & Co. LLC, William Blair & Company, L.L.C.
Use of proceeds: To facilitate greater access to the Company's securities on the Nasdaq stock exchange
Aug 20, 2026
1.50 per cent convertible notes due 2031
Made bigger: US$600M · J.P. Morgan Securities plc
Dealers: J.P. Morgan Securities plc (lead)
Use of proceeds: Refinancing of existing convertible bonds alongside a concurrent repurchase
Apr 15, 2026

Open Financings · Read by 6ix AI from the company's releases

IPO

Withdrawn on Jun 14, 2024. Filed with the SEC to go public on May 17, 2024.

ADSs offered
17,000,000 American depositary shares
Listing
TLX on the Nasdaq Global Market · Has applied to list
Underwriters
Jefferies, Morgan Stanley, Truist Securities, William Blair · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceJan 25, 2024
Filed publiclyMay 17, 2024
Amended onceJun 5, 2024
Filing withdrawnJun 14, 2024

Open IPO · From the cover of the amended prospectus (F-1/A) filed Jun 5, 2024

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue803.8M516.6M333.0M160.1M7.60M5.21M3.48M195.1K403.5K0
Cost of revenue377.4M180.4M123.4M130.8M37.4M2.02M15.4M03.79K0
Gross profit426.4M336.2M209.5M29.3M-29.8M3.19M-11.9M195.1K-3.79K0
Research and development171.2M127.9M85.3M57.9M34.1M23.1M21.2M18.7M2.98M10.0K
Selling, general and administrative94.0M49.1M41.1M18.0M11.3M8.50M2.46M20.0K
Operating income29.8M55.2M11.0M-73.2M-81.2M-49.3M-40.3M-27.6M-6.52M-30.0K
Depreciation and amortization21.4M5.28M4.16M5.38M5.17M4.88M4.24M6.97K3.79K30.0K
EBITDA51.2M60.5M15.2M-67.8M-76.1M-44.4M-36.0M-27.6M-6.52M0
Interest expense181.0K64.0K97.0K406.0K189.0K1.18M2.41M29.0K9.40K0
Income before tax-5.27M37.9M2.59M-98.6M-99.0M-60.3M-42.8M-15.7M-6.38M-44.0K
Income tax1.86M4.23M-1.61M5.46M-18.5M-15.4M-14.9M-1.88M-403.5K-14.0K
Net income-7.13M33.7M4.21M-104.1M-80.5M-44.9M-27.9M-13.8M-6.38M-44.0K
Earnings per share, basic-0.020.100.01-0.34-0.29-0.17-0.12-0.07-0.05-0.00
Earnings per share, diluted-0.020.100.01

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents141.9M440.0M84.3M116.3M22.0M77.9M44.6M25.8M48.8M
Receivables129.2M86.9M44.0M45.9M20.8M14.2M13.0M8.44M488.8K
Inventory37.1M23.6M12.7M8.48M3.45M633.0K542.0K642.5K297.2K
Current assets330.3M570.1M158.7M173.2M47.5M93.6M58.7M35.9M49.5M
Property, plant and equipment58.7M27.8M15.8M18.8M6.33M4.82M1.90M226.0K5.39K
Goodwill199.0M66.6M5.52M4.10M4.22M4.22M3.14M332.5K
Total assets1.16B940.4M277.3M255.4M109.8M157.8M102.6M76.7M51.1M
Accounts payable150.3M86.8M54.3M16.8M11.9M5.81M6.96M3.25M275.8K
Current liabilities231.6M205.1M111.4M85.6M38.0M20.0M10.6M8.24M1.47M
Long-term debt391.9M341.8M5.95M3.31M095.0K292.0K596.3K
Total debt405.0M353.6M6.61M10.4M2.54M2.21M2.13M1.73M345.4K
Total liabilities748.6M587.4M174.6M175.3M106.2M78.8M32.5M23.8M1.80M
Shareholders' equity415.4M352.9M102.6M80.0M2.16M79.0M70.1M52.9M49.3M
Shares outstanding337.9M310.6M282.2M257.3M233.4M202.1M128.0M128.0M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-17.3M27.5M14.3M-64.0M-59.3M1.96M-23.3M-20.7M-6.03M-6.03M
Capital spending-25.7M-9.12M-6.31M-13.9M-1.34M-322.0K-468.0K-403.0K-5.64K-5.64K
Free cash flow-43.0M18.4M7.97M-77.8M-60.7M1.64M-23.8M-20.7M-6.04M-6.04M
Cash from investing-285.9M-86.7M-16.8M-17.0M-2.73M-1.09M-468.0K-2.69M-1.26K-1.26K
Cash from financing-3.72M416.8M7.09M175.0M2.85M34.1M42.7M-869.4K54.8M54.8M
Dividends paid-168.4M-34.5M-54.8M
Share buybacks1.81M-7.82M3.78M-130.0K45.3M0-2.99M58.6M
Change in cash-306.9M357.6M4.53M94.3M-55.9M33.3M18.8M-23.0M54.8M48.8M

Open Financials

Filings

FilingDateTypeFiled with
Appendix 3Y Maria RivasNov 4, 2026Other filingsASX
Telix Capital Markets Day Presentation November 2026Nov 3, 2026Other filingsASX
Change of Director's Interest Notice - Marie McDonaldNov 3, 2026Ownership change noticeASX
Notification regarding unquoted securities - TLXNov 3, 2026Other filingsASX
Cancellation of Appendix 2ANov 2, 2026FinancingASX
Telix Notice of General Meeting, Proxy Form and Online GuideOct 29, 2026Meeting noticeASX
6-K · Report of a foreign issuerOct 29, 2026Current reportSEC
Application for quotation of securities - TLXOct 28, 2026FinancingASX
Appendix 3Y Dr Christian BehrenbruchOct 26, 2026Other filingsASX
Appendix 3Y William JellisonOct 25, 2026Other filingsASX
Show 200 filings
FilingDateTypeFiled with
Appendix 3Y Change in Director Interest - D GillOct 25, 2026Management or board changeASX
6-K · Report of a foreign issuerOct 20, 2026Current reportSEC
Telix Reports Third Quarter 2026 Financial PerformanceOct 20, 2026Quarterly reportASX
Telix Reports Third Quarter 2026 Financial PerformanceOct 20, 2026Quarterly reportASX
Notification of cessation of securities - TLXOct 4, 2026FinancingASX
Notification regarding unquoted securities - TLXOct 4, 2026Other filingsASX
Application for quotation of securities - TLXOct 4, 2026FinancingASX
6-K · Report of a foreign issuerSep 29, 2026Current reportSEC
FDA Fast Track for BiPASS Pre Biopsy Prostate ImagingSep 29, 2026Operations updateASX
Change in substantial holdingSep 25, 2026Ownership change noticeASX
Appendix 3Y Change in Director Interest-D GillSep 25, 2026Management or board changeASX
Application for quotation of securities - TLXSep 25, 2026FinancingASX
Grant of waivers of Listing Rule 7.3.4Sep 21, 2026Acquisition or disposalASX
6-K · Report of a foreign issuerSep 21, 2026Current reportSEC
Telix and ITM Join Forces to Create Radiopharma PowerhouseSep 20, 2026Other filingsASX
Telix and ITM Join Forces to Create Radiopharma PowerhouseSep 20, 2026Acquisition or disposalASX
4 · Change in ownershipSep 14, 2026Insider tradeSEC
6-K · Report of a foreign issuerSep 14, 2026Current reportSEC
Application for quotation of securities - TLXSep 14, 2026FinancingASX
FDA Approves Telix Brain Cancer Imaging Drug PixclaraSep 13, 2026Operations updateASX
6-K · Report of a foreign issuerSep 1, 2026Current reportSEC
Telix Completes Enrollment in Phase 3 BiPASS StudySep 1, 2026Operations updateASX
6-K · Report of a foreign issuerAug 31, 2026Current reportSEC
6-K · Report of a foreign issuerAug 19, 2026Current reportSEC
Telix HY26 Results PresentationAug 19, 2026Other filingsASX
Telix HY26 Results AnnouncementAug 19, 2026ResultsASX
Telix HY26 Appendix 4D and Interim ReportAug 19, 2026Interim reportASX
Telix H1 2026 Results - Investor Webcast NotificationJul 30, 2026Other filingsASX
6-K · Report of a foreign issuerJul 21, 2026Current reportSEC
Q2 2026 Revenue US$247M Strong Momentum Pipeline ProgressJul 20, 2026ResultsASX
6-K · Report of a foreign issuerJul 2, 2026Current reportSEC
FDA Alignment to Advance ProstACT Global Phase 3 TrialJul 1, 2026Other filingsASX
6-K · Report of a foreign issuerMay 21, 2026Current reportSEC
3 · Initial statement of ownershipMay 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 18, 2026Insider tradeSEC
4 · Change in ownershipMay 6, 2026Insider tradeSEC
UPLOAD · Letter from the SECApr 23, 2026Other filingsSEC
6-K · Report of a foreign issuerApr 22, 2026Current reportSEC
6-K · Report of a foreign issuerApr 21, 2026Current reportSEC
6-K · Report of a foreign issuerApr 20, 2026Current reportSEC
CORRESP · Letter to the SECApr 17, 2026Other filingsSEC
Telix Successfully Prices Upsized US$600M Convertible BondsApr 14, 2026FinancingASX
6-K · Report of a foreign issuerApr 14, 2026Current reportSEC
Telix Investor Presentation April 2026Apr 14, 2026Other filingsASX
Telix Refinances Convertible BondsApr 14, 2026FinancingASX
6-K · Report of a foreign issuerApr 14, 2026Current reportSEC
6-K · Report of a foreign issuerApr 13, 2026Current reportSEC
Telix and Regeneron Announce Radiopharma CollaborationApr 12, 2026Operations updateASX
FDA Accepts NDA for TLX101-Px (Pixclara)Apr 9, 2026Operations updateASX
6-K · Report of a foreign issuerApr 9, 2026Current reportSEC
6-K · Report of a foreign issuerApr 8, 2026Current reportSEC
6-K · Report of a foreign issuerApr 7, 2026Current reportSEC
Q1 2026 Strong Revenue Growth and Tx Pipeline AdvancementApr 6, 2026ResultsASX
UPLOAD · Letter from the SECApr 3, 2026Other filingsSEC
6-K · Report of a foreign issuerApr 2, 2026Current reportSEC
4 · Change in ownershipApr 1, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 1, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 1, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 1, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 1, 2026Insider tradeSEC
20-F/A · Annual report, amendedMar 20, 2026Annual reportSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
6-K · Report of a foreign issuerMar 16, 2026Current reportSEC
Telix Resubmits NDA to FDA for Pixclara Brain Cancer ImagingMar 15, 2026Operations updateASX
6-K · Report of a foreign issuerMar 10, 2026Current reportSEC
ProstACT Global Phase 3 (Part 1) Results PresentationMar 9, 2026Other filingsASX
ProstACT Global Phase 3 (Part 1) Achieves Primary ObjectivesMar 9, 2026Other filingsASX
F-3ASRFeb 20, 2026Other filingsSEC
2025 Full Year Results PresentationFeb 19, 2026ResultsASX
Appendix 4E and 2025 Annual ReportFeb 19, 2026Annual reportASX
2025 Full Year Results AnnouncementFeb 19, 2026ResultsASX
20-F · Annual reportFeb 19, 2026Annual reportSEC
6-K · Report of a foreign issuerFeb 19, 2026Current reportSEC
6-K · Report of a foreign issuerFeb 18, 2026Current reportSEC
Telix Submits EU MAA for TLX101-Px Brain Cancer ImagingFeb 17, 2026Operations updateASX
6-K · Report of a foreign issuerFeb 2, 2026Current reportSEC
6-K · Report of a foreign issuerJan 20, 2026Current reportSEC
Telix Achieves FY25 Guidance - US$804M, Q4 GrowthJan 20, 2026ResultsASX
Chinese NMPA Accepts New Drug Application for IlluccixJan 19, 2026Operations updateASX
6-K · Report of a foreign issuerJan 12, 2026Current reportSEC
6-K · Report of a foreign issuerDec 22, 2025Current reportSEC
Precision Medicine Portfolio UpdateDec 21, 2025Operations updateASX
6-K · Report of a foreign issuerDec 17, 2025Current reportSEC
ProstACT Global Study StatusDec 17, 2025Other filingsASX
6-K · Report of a foreign issuerDec 8, 2025Current reportSEC
1st Patient Dosed in ProstACT Global Randomized Tx ExpansionDec 7, 2025Operations updateASX
6-K · Report of a foreign issuerOct 14, 2025Current reportSEC
Telix Reports US$206M Revenue, FY 2025 Guidance UpgradedOct 14, 2025GuidanceASX
6-K · Report of a foreign issuerSep 23, 2025Current reportSEC
CMS Grants Transitional Pass-Through Status for GozellixSep 22, 2025Operations updateASX
Telix and FDA Agree Resubmission Pathway for Pixclara NDASep 8, 2025Other filingsASX
6-K · Report of a foreign issuerSep 8, 2025Current reportSEC
6-K · Report of a foreign issuerAug 28, 2025Current reportSEC
Telix Provides Regulatory Update on TLX250-CDxAug 27, 2025Legal or regulatory actionASX
Telix H1 2025 Results AnnouncementAug 20, 2025ResultsASX
Telix H1 2025 Results PresentationAug 20, 2025ResultsASX
Telix H1 2025 Appendix 4D and Interim ReportAug 20, 2025Interim reportASX
6-K · Report of a foreign issuerAug 20, 2025Current reportSEC
Historical Financials in USD and H12025 OPEX (Unaudited)Aug 4, 2025ResultsASX
6-K · Report of a foreign issuerJul 22, 2025Current reportSEC
Telix Reports US$204M Q2 Revenue, Up 63% YOYJul 22, 2025Other filingsASX
6-K · Report of a foreign issuerJul 9, 2025Current reportSEC
Gozellix Receives Permanent HCPCS CodeJul 9, 2025Operations updateASX
6-K · Report of a foreign issuerJun 11, 2025Current reportSEC
Telix Investor Day PresentationJun 11, 2025Other filingsASX
6-K · Report of a foreign issuerMay 21, 2025Current reportSEC
6-K · Report of a foreign issuerApr 28, 2025Current reportSEC
Telix Provides Regulatory Update on TLX101-CDxApr 27, 2025Legal or regulatory actionASX
6-K · Report of a foreign issuerApr 22, 2025Current reportSEC
Telix Reports US$186M Q1 Revenue, Up 62% YOYApr 22, 2025Other filingsASX
6-K · Report of a foreign issuerApr 17, 2025Current reportSEC
6-K · Report of a foreign issuerApr 17, 2025Current reportSEC
6-K · Report of a foreign issuerApr 7, 2025Current reportSEC
6-K · Report of a foreign issuerApr 3, 2025Current reportSEC
FDA Approves New Prostate Cancer Imaging Agent GozellixMar 20, 2025Operations updateASX
6-K · Report of a foreign issuerMar 20, 2025Current reportSEC
6-K · Report of a foreign issuerMar 18, 2025Current reportSEC
6-K · Report of a foreign issuerMar 12, 2025Current reportSEC
Telix Completes FAP-Targeting Theranostic AcquisitionMar 11, 2025Acquisition or disposalASX
6-K · Report of a foreign issuerFeb 26, 2025Current reportSEC
6-K · Report of a foreign issuerFeb 26, 2025Current reportSEC
FDA accepts BLA and grants priority review for ZircaixFeb 25, 2025Other filingsASX
6-K · Report of a foreign issuerFeb 25, 2025Current reportSEC
Telix Announces Change in Reporting Currency to USDFeb 24, 2025Other filingsASX
6-K · Report of a foreign issuerFeb 24, 2025Current reportSEC
20-F · Annual reportFeb 24, 2025Annual reportSEC
6-K · Report of a foreign issuerFeb 21, 2025Current reportSEC
2024 Full Year Results PresentationFeb 20, 2025ResultsASX
2024 Full Year Results AnnouncementFeb 20, 2025ResultsASX
Appendix 4E and 2024 Annual ReportFeb 20, 2025Annual reportASX
SCHEDULE 13G · Big-stake noticeFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 14, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerFeb 13, 2025Current reportSEC
Illuccix Approved in the United KingdomFeb 12, 2025Operations updateASX
6-K · Report of a foreign issuerJan 31, 2025Current reportSEC
Telix Completes Acquisition of Tx Assets, Biologics PlatformJan 30, 2025Acquisition or disposalASX
Telix Completes Acquisition of RLS (USA) IncJan 27, 2025Acquisition or disposalASX
6-K · Report of a foreign issuerJan 27, 2025Current reportSEC
Illuccix Receives European ApprovalJan 16, 2025Operations updateASX
6-K · Report of a foreign issuerJan 16, 2025Current reportSEC
6-K · Report of a foreign issuerJan 13, 2025Current reportSEC
6-K · Report of a foreign issuerJan 13, 2025Current reportSEC
Telix JP Morgan Healthcare Conference 2025 PresentationJan 13, 2025Other filingsASX
Telix Exceeds FY24 Guidance with US$142M Q4 RevenueJan 13, 2025GuidanceASX
Presentation to Accompany Biologics Platform AcquisitionJan 12, 2025Acquisition or disposalASX
TLX to Acquire Next-Gen Therapeutics and Biologics PlatformJan 12, 2025Acquisition or disposalASX
6-K · Report of a foreign issuerDec 30, 2024Current reportSEC
S-8 · Registration statement for employee plansDec 19, 2024Offer documentSEC
SEC STAFF LETTERNov 21, 2024Other filingsSEC
6-K · Report of a foreign issuerNov 19, 2024Current reportSEC
Presentation to Accompany FAP-Targeting AcquisitionNov 18, 2024Acquisition or disposalASX
Telix Adds FAP-Targeting Theranostic Candidates to PipelineNov 18, 2024Other filingsASX
6-K · Report of a foreign issuerNov 14, 2024Current reportSEC
EFFECT · Notice that a registration is effectiveNov 13, 2024Other filingsSEC
SEC STAFF ACTIONNov 12, 2024Other filingsSEC
CERT · Exchange's certificate of listingNov 12, 2024Other filingsSEC
CORRESP · Letter to the SECNov 12, 2024Other filingsSEC
CMS payment improvement decision for radiopharma diagnosticsNov 3, 2024Operations updateASX
SEC STAFF LETTEROct 30, 2024Other filingsSEC
20FR12B/AOct 29, 2024Other filingsSEC
FDA accepts NDA and grants priority review for PixclaraOct 23, 2024Operations updateASX
Telix Files Form 20-F Registration Statement for Nasdaq ADSOct 17, 2024Other filingsASX
F-6Oct 17, 2024Other filingsSEC
CORRESP · Letter to the SECOct 17, 2024Other filingsSEC
20FR12BOct 17, 2024Other filingsSEC
Telix Q3 2024 Revenue and Business UpdateOct 17, 2024ResultsASX
UPLOAD · Letter from the SECOct 10, 2024Other filingsSEC
Telix to Acquire RLS for US Manufacturing and DistributionSep 22, 2024Acquisition or disposalASX
DRS · Draft registration statementSep 13, 2024Offer documentSEC
Telix Submits NDA for TLX101-CDx Brain Cancer Imaging AgentAug 27, 2024Operations updateASX
Telix 1H 2024 Results ReleaseAug 22, 2024ResultsASX
Telix 1H 2024 Results PresentationAug 22, 2024Other filingsASX
Telix 1H 2024 Appendix 4D and Interim ReportAug 22, 2024Interim reportASX
Telix Completes A$650 Million of Convertible BondsJul 30, 2024FinancingASX
Convertible Bond Cleansing NoticeJul 29, 2024FinancingASX
Telix Successfully Prices A$650M Convertible BondsJul 23, 2024FinancingASX
Telix Announces A$600 Million Convertible Bonds OfferingJul 23, 2024FinancingASX
Telix Q2 2024 Revenue/Business Highlights, Guidance UpgradeJul 17, 2024ResultsASX
CMS proposes payment improvement for radiopharma diagnosticsJul 11, 2024Operations updateASX
RW · Request to withdraw a registrationJun 14, 2024Other filingsSEC
RW · Request to withdraw a registrationJun 14, 2024Other filingsSEC
Telix Elects to Withdraw from Proposed U.S. ListingJun 13, 2024Other filingsASX
Trading HaltJun 12, 2024Trading halt or suspensionASX
8-A12B · Registration of shares for listing on an exchangeJun 10, 2024Other filingsSEC
Telix Launches Proposed US IPOJun 5, 2024Offer documentASX
F-1/A · Registration statement, amendedJun 5, 2024Offer documentSEC
Telix Completes TLX250-CDx (Zircaix) BLA SubmissionJun 2, 2024Operations updateASX

This page holds 200 of 441 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Telix Pharmaceuticals Limited’s releases · as of Aug 20, 2026

Common shares
338,777,049
Fully diluted
338,777,049

Fully diluted

LineShares
Common shares338,777,049

Share count over time

CountShares
Nov 22, 2026338,777,049

Open Cap table

Shareholders

Institutions

HolderSharesValueAs of
Armistice Capital, LLC1.67MUS$18.3MSep 30, 2026
Fidelity551KUS$6.04MSep 30, 2026
Blair William & Co481KUS$5.27MSep 30, 2026
Farallon Capital Management, L.L.C.419KUS$4.6MSep 30, 2026
ArrowMark Colorado Holdings LLC392KUS$4.3MSep 30, 2026
Lazard Asset Management LLC291KUS$3.2MSep 30, 2026
Portland Investment Counsel Inc.266KUS$2.92MSep 30, 2026
Hennion & Walsh Asset Management, Inc.216KUS$2.37MSep 30, 2026
Private Advisor Group, LLC204KUS$2.24MSep 30, 2026
Integrated Wealth Concepts LLC165KUS$1.8MSep 30, 2026
Show 50 holders
HolderSharesValueAs of
Raiffeisen Bank International AG110KUS$1.25MSep 30, 2026
Aubrey Capital Management Ltd105KUS$1.15MSep 30, 2026
UBS97,163US$1.07MSep 30, 2026
JPMorgan63,172US$716KSep 30, 2026
Vanguard60,453US$663KSep 30, 2026
Orion Porfolio Solutions, LLC48,757US$535KSep 30, 2026
SummitTX Capital, L.P.46,187US$507KSep 30, 2026
Mariner, LLC42,844US$470KSep 30, 2026
Two Sigma37,804US$415KSep 30, 2026
Marshall Wace, LLP37,502US$411KSep 30, 2026
Balyasny Asset Management L.P.37,124US$407KSep 30, 2026
IHT Wealth Management, LLC33,145US$364KSep 30, 2026
Morgan Stanley29,941US$328KSep 30, 2026
BNP Paribas28,500US$313KSep 30, 2026
Portolan Capital Management, LLC25,782US$283KSep 30, 2026
Jain Global LLC20,240US$222KSep 30, 2026
Millennium19,981US$219KSep 30, 2026
WoodTrust Financial Corp17,000US$186KSep 30, 2026
Goldman Sachs15,426US$169KSep 30, 2026
RBC14,698US$161KSep 30, 2026
Osaic Holdings, Inc.13,794US$151KSep 30, 2026
HSBC12,730US$140KSep 30, 2026
Oak Associates LTD12,244US$134KSep 30, 2026
Bank of America12,038US$132KSep 30, 2026
Vident Advisory, LLC11,137US$122KSep 30, 2026
Natixis7,387US$81,442Sep 30, 2026
Rhumbline Advisers7,168US$78,625Sep 30, 2026
Calydon Capital3,549US$38,933Sep 30, 2026
Berthel, Fisher & Company Financial Services, Inc.3,000US$32,910Sep 30, 2026
Arax Advisory Partners2,523US$27,675Sep 30, 2026
Clearstead Advisors, LLC2,112US$23,169Sep 30, 2026
NewEdge Advisors, LLC1,920US$21,062Sep 30, 2026
BlackRock1,709US$18,746Sep 30, 2026
Superior Planning, LLC1,314US$14,414Sep 30, 2026
GAMMA Investing LLC1,128US$12,374Sep 30, 2026
Nuveen1,071US$12,145Sep 30, 2026
EverSource Wealth Advisors, LLC1,040US$11,409Sep 30, 2026
Jones Financial Companies Lllp917US$10,500Sep 30, 2026
Steward Partners Investment Advisory, LLC900US$9,873Sep 30, 2026
Larson Financial Group LLC899US$9,862Sep 30, 2026

This page holds 50 of 74 holders. Open Shareholders

Funds

HolderSharesValueAs of
Vanguard Total International Stock Index Fund4.1MUS$40.8MJul 31, 2026
Vanguard Developed Markets Index Fund2.74MUS$31.8MJun 30, 2026
iShares Core MSCI EAFE ETF2.07MUS$20.5MJul 31, 2026
The Asia Pacific Small Company Series1.13MUS$11.2MJul 31, 2026
iShares MSCI EAFE Small-Cap ETF998KUS$9.91MJul 31, 2026
Strategic Advisers U.S. Total Stock Fund753KUS$7.29MMay 31, 2026
State Street(R) SPDR(R) Portfolio Developed World ex-US ETF686KUS$7.87MJun 30, 2026
Vanguard Ftse All-World Ex-Us Index Fund652KUS$6.48MJul 31, 2026
Schwab International Equity ETF614KUS$5.75MMay 31, 2026
iShares Core MSCI Total International Stock ETF407KUS$4.05MJul 31, 2026
All 48 holders
HolderSharesValueAs of
iShares Core MSCI International Developed Markets ETF357KUS$3.55MJul 31, 2026
Vanguard Pacific Stock Index Fund298KUS$2.96MJul 31, 2026
Vanguard Total World Stock Index Fund233KUS$2.32MJul 31, 2026
College Retirement Equities Fund - Total Global Stock Account203KUS$2.35MJun 30, 2026
Fidelity Total International Index Fund157KUS$1.56MJul 31, 2026
International Small Cap Portfolio146KUS$1.7MJun 30, 2026
Fidelity ZERO International Index Fund89,507US$889KJul 31, 2026
Fidelity SAI International Small Cap Index Fund80,421US$799KJul 31, 2026
State Street Global All Cap Equity ex-U.S. Index Portfolio76,534US$879KJun 30, 2026
iShares Core MSCI Pacific ETF76,066US$756KJul 31, 2026
Dimensional International Small Cap ETF63,699US$636KJul 31, 2026
Vanguard ESG International Stock ETF53,283US$501KMay 31, 2026
Dimensional International Core Equity Market ETF51,734US$516KJul 31, 2026
iShares International Small-Cap Equity Factor ETF51,629US$513KJul 31, 2026
Ershares Global Entrepreneurs33,555US$385KJun 30, 2026
Fidelity Flex International Index Fund31,213US$310KJul 31, 2026
Dimensional International Core Equity 2 ETF27,798US$277KJul 31, 2026
International Small Cap Growth Portfolio27,127US$270KJul 31, 2026
iShares MSCI World Small-Cap ETF15,770US$148KMay 31, 2026
Franklin FTSE Australia ETF14,739US$169KJun 30, 2026
State Street(R) SPDR(R) Portfolio MSCI Global Stock Market ETF14,597US$168KJun 30, 2026
VIP International Index Portfolio10,437US$121KJun 30, 2026
World ex U.S. Core Equity Portfolio8,707US$86,511Jul 31, 2026
ActivePassive International Equity ETF7,685US$76,355May 31, 2026
Dimensional World ex. U.S. Core Equity 2 ETF5,701US$56,898Jul 31, 2026
AQR Trend Total Return Fund5,392US$62,528Jun 30, 2026
River Oak Discovery Fund4,745US$49,450Jul 31, 2026
Fidelity Nasdaq Composite Index Fund4,455US$44,264May 31, 2026
Destinations International Equity Fund4,144US$38,903May 31, 2026
FlexShares Morningstar Developed Markets ex-US Factor Tilt Index Fund4,018US$40,101Jul 31, 2026
International Sustainability Core 1 Portfolio3,852US$38,273Jul 31, 2026
LVIP Dimensional International Core Equity Fund3,758US$43,579Jun 30, 2026
Steward Values Enhanced International Fund3,742US$38,996Jul 31, 2026
Schwab International Opportunities Fund2,383US$23,677Jul 31, 2026
AZL DFA International Core Equity Fund1,382US$15,953Jun 30, 2026
AQR CVX Fusion Fund268US$3,108Jun 30, 2026
Avantis Responsible International Equity ETF60US$564May 31, 2026
Avantis International Small Cap Equity ETF27US$254May 31, 2026

Insider trades

TradeTradeSharesPriceValueDate
Maria Rivas
Director
Buy9,000USD 9.03US$81,306Oct 30, 2026
Dr Christian Behrenbruch
Director
Buy38,750AUD 12.89AUD 500KOct 26, 2026
David Gill
Director
Buy3,250AUD 9.19AUD 29,881Oct 23, 2026
William Jellison
Director
Buy25,000AUD 9.49AUD 237KOct 22, 2026
Smith Darren Charlton
Officer: Group Chief Financial Officer
Buy2,071USD 9.66US$20,006Sep 7, 2026
Behrenbruch Christian
Director, Officer: MD & Group CEO
Buy33,435USD 14.87US$497KApr 29, 2026
Behrenbruch Christian
Director, Officer: MD & Group CEO
Buy34,500USD 14.48US$500KApr 28, 2026

Big stakes

StakeStakeSharesDateFiling
Behrenbruch Christian6.97%23.3MNov 12, 2024Schedule 13G
Gnosis Verwaltungsgesellschaft m.b.H.6.78%22.7MNov 12, 2024Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
David Gill
Other companies: Y mAbs Therapeutics (Director · Since at least Sep 20, 2018); Evolus, Inc. Common Stock (Director · Since at least Feb 12, 2018); Strongbridge Biopharma plc (Director · Sep 3, 2019 – Oct 5, 2021 · Past); STRATA Skin Sciences, Inc. (Director · May 30, 2018 – Nov 22, 2019 · Past); Melinta Therapeutics Inc (Director · May 25, 2018 – Jun 11, 2019 · Past); Ocugen, Inc. (Director · Dec 9, 2016 – Jun 15, 2018 · Past); Cempra Inc (Director · Jan 1, 2016 – Jan 3, 2017 · Past); EndoChoice Holdings Inc (President and CFO · Aug 14, 2015 – Nov 22, 2016 · Past)
Chair & Independent Non-Executive Director · Since Apr 2, 2026
William Jellison
Other companies: Medtronic plc. (Director · Since at least Aug 19, 2025); Masimo Corporation (Director · Since at least Sep 19, 2024); Anika Therapeutics Inc. (Director · Since at least May 28, 2024); Avient Corporation (Director · Since at least Oct 7, 2015); Stryker Corporation (VP and CFO · Apr 22, 2013 – Feb 11, 2015 · Past); Dentsply Sirona Inc. (Sr. VP & C.F.O. · Feb 13, 2006 – Apr 12, 2013 · Past)
Independent Non-Executive Director · Since at least May 11, 2026
Maria Rivas
Other companies: The Cooper Companies, Inc. (Director · Since at least Jul 1, 2021); Medidata Solutions Inc (Director · Oct 19, 2018 – Oct 28, 2019 · Past)
Independent Non-Executive Director · Since at least May 11, 2026
Annie KasparianInvestor Relations · Since at least Sep 1, 2026
Charlene Jaw AssociateDirector Investor Relations · Since at least Jun 23, 2026
Christian BehrenbruchManaging Director & Group Chief Executive Officer · Since at least Mar 18, 2026
Christian KrautkramerGroup General Counsel · Since at least Nov 5, 2026
Craig UlrickChief Information Officer · Since at least Nov 5, 2026
Darren PattiGroup Chief Operating Officer · Since at least Jun 4, 2025
Darren SmithGroup Chief Financial Officer · Since at least Mar 18, 2026
All 25 people
PersonSeat
David CadeGroup Chief Medical Officer · Since at least Mar 18, 2026
Jann SkinnerIndependent Non-Executive Director · Since at least Mar 18, 2026
Kenneth ClarkeSVP, Global Regulatory Affairs · Since at least Nov 5, 2026
Kevin RichardsonTelix Precision Medicine · Until May 6, 2026 · Past
Kyahn WilliamsonSVP, Investor Relations & Corporate Communications · Since at least Jun 23, 2026
Marie McDonaldIndependent Non-Executive Director · Since at least Mar 18, 2026
Mark NelsonIndependent Non-Executive Director · Since at least Mar 18, 2026
Mary JesselGroup Chief of Clinical Affairs · Since at least May 20, 2025
Meredith CroweSVP, Global People & Culture · Since at least Nov 5, 2026
Paul SchafferSVP, Research & Development · Since at least Nov 5, 2026
Radu CiocanSVP, TMS Radiopharmaceutical Operations · Since at least Nov 5, 2026
Raphaël OrtizTelix International · May 1, 2026 – May 6, 2026 · Past
Richard ValeixTelix Therapeutics · Until May 6, 2026 · Past
Thorsten MelcherSVP, Global Business Development and Alliance Management · Since at least Nov 5, 2026
Tom FrommSVP, Corporate Sales · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about Telix Pharmaceuticals Limited.